Stock Chart
MNKD
This target is derived from long-term trendline analysis and projected growth.
Note: Targets are based on the assumption that the current primary trend continues. They should be used as reference points, not guarantees.
Target may adjust dynamically as the stock trend reverses or accelerates.
Type: SELL growth_1yr
Strike: $5
Premium: $1.80
Expiry: Jan 15, 2027
Target: $5
Score: -96
LEAPs are long-term options (1+ year) with less time decay.
This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.
How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future
Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling
⚠️ Not a prediction. Shows trend projection only.
R-squared: 0.21
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About MNKD - Mannkind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Key Statistics
More MNKD Analysis
This MNKD stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track MNKD's price movements with trendlines, gamma walls, and key support/resistance levels.